Röjdmark S, Andersson D E, Hed R, Sundblad L
Horm Metab Res. 1981 Dec;13(12):664-7. doi: 10.1055/s-2007-1019369.
The current study was performed in order to investigate whether verapamil would affect the glucose response to glucagon differently in patients with non insulin-dependent diabetes mellitus (NIDDM) compared with age-matched normoglycemic controls. For that purpose glucagon was injected intravenously on a background infusion of verapamil, and for comparison also on a background infusion of saline in these two groups. Verapamil was found to blunt the glucose response to glucagon in the patients with NIDDM, whereas it augmented the glucose response to glucagon in the controls. This discrepancy could not be explained on the basis of verapamil-induced changes in the release of insulin, since verapamil did not effect the serum responses to glucagon. However, it could reflect the differences in hepatic handling of glucose, which has been shown to prevail in patients with NIDDM compared with healthy controls.
进行本研究是为了调查与年龄匹配的血糖正常对照组相比，维拉帕米是否会对非胰岛素依赖型糖尿病（NIDDM）患者对胰高血糖素的葡萄糖反应产生不同影响。为此，在维拉帕米背景输注的情况下静脉注射胰高血糖素，并且为了进行比较，在这两组中也在生理盐水背景输注的情况下静脉注射胰高血糖素。结果发现，维拉帕米可减弱NIDDM患者对胰高血糖素的葡萄糖反应，而在对照组中，它增强了对胰高血糖素的葡萄糖反应。这种差异不能基于维拉帕米引起的胰岛素释放变化来解释，因为维拉帕米对血清对胰高血糖素的反应没有影响。然而，这可能反映了肝脏对葡萄糖处理的差异，与健康对照组相比，NIDDM患者中这种差异已被证明是普遍存在的。
